Dr. Reddy's Biologics Facility in Hyderabad Receives USFDA Form 483 with Five Observations
The USFDA has completed a Pre-Approval Inspection (PAI) at Dr. Reddy's biologics manufacturing facility in Bachupally, Hyderabad, with five observations.
Quality / GMP | 13/09/2025 | By Dineshwori | 322
Cohance's Jaggaiahpet API Plant Clears USFDA Inspection with Zero 483 Observations
The United States Food and Drug Administration (USFDA) has completed a general current Good Manufacturing Practices (cGMP) audit at Cohance Lifesciences' API manufacturing facility (API Unit1) located at Jaggaiahpet, Andhra Pradesh, with zero Form 483 observations.
Quality / GMP | 12/09/2025 | By Dineshwori | 320
Sun Pharma Halol Facility Classified OAI by US FDA, Shipments Restricted
The US Food and Drug Administration (FDA) has classified Sun Pharma's Halol facility as “Official Action Indicated” (OAI) following an inspection conducted between June 2 and June 13, 2025.
Quality / GMP | 10/09/2025 | By Dineshwori | 450
Akums's Hormonal Plant Gets EAEU GMP Nod, Expands into Eurasia
Akums’s Hormonal Plant receives EAEU GMP certification for oral hormonal tablets, enabling entry into Eurasian markets with therapies for women’s health, HRT and endocrine care.
Quality / GMP | 09/09/2025 | By Dineshwori | 179
Lupin's Aurangabad Facility Gets Two Observations After US FDA Inspection
The United States Food and Drug Administration (US FDA) has completed a product-specific pre-approval inspection at Lupin’s Chhatrapati Sambhajinagar (Aurangabad) manufacturing facility, issuing two observations.
Quality / GMP | 06/09/2025 | By Dineshwori | 740
US FDA Completes Inspection at Aurobindo Pharma's Telangana Unit
The inspection of Aurobindo Pharma’s Apitoria Unit-I facility, conducted from 21-29 August, 2025, concluded with five observations.
Quality / GMP | 30/08/2025 | By Dineshwori | 368
Veranova's Devens Site Clears FDA Inspection with Zero Observations
Veranova's Devens site has successfully completed a routine current Good Manufacturing Practice (cGMP) surveillance inspection by the Food and Drug Administration (FDA).
Quality / GMP | 14/08/2025 | By Dineshwori | 208
No Physical Applications For WHO-GMP (COPP) Approvals After August 15: CDSCO
The Drugs Controller General of India has directed all zonal and sub-zonal offices of the Central Drugs Standard Control Organization (CDSCO) to stop accepting physical applications for WHO-GMP (Certificate of Pharmaceutical Product – COPP) after August 15, 2025.
Quality / GMP | 08/08/2025 | By Dineshwori | 317
Cipla's Bommasandra Facility Gets VAI Classification from USFDA
Cipla has announced that its manufacturing facility in Bommasandra, Bengaluru, has received a Voluntary Action Indicated (VAI) classification from the USFDA following a recent inspection.
Quality / GMP | 06/08/2025 | By Dineshwori | 206
Torrent Pharma's Vizag API Unit Passes USFDA Inspection with Zero Observation
The US Food and Drug Administration (USFDA) has completed the inspection of Torrent Pharma's API manufacturing facility located in Vizag, Andhra Pradesh.
Quality / GMP | 04/08/2025 | By Dineshwori | 453
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy